Multicenter phase II trial of adjuvant therapy for resected pancreatic cancer using cisplatin, 5-fluorouracil, and interferon-alfa-2b-based chemoradiation: ACOSOG Trial Z05031

Annals of Oncology

Volumn 22, Issue 2, 2011, Pages 348-354

  Picozzi, V J ^a   Abrams, R A ^b   Decker, P A ^c   Traverso, W ^a   O'Reilly, E M ^d   Greeno, E ^e   Martin, R C ^f   Wilfong, L S ^g   Rothenberg, M L ^h   Posner, M C ⁱ   Pisters, P W T ^j  

^a VIRGINIA MASON MEDICAL CENTER   (United States)

^b RUSH UNIVERSITY MEDICAL CENTER   (United States)

^c MAYO CLINIC   (United States)

^d MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

^e UNIVERSITY OF MINNESOTA   (United States)

^f Department of Surgery ^*  (United States)

^g TEXAS ONCOLOGY   (United States)

^h VANDERBILT INGRAM CANCER CENTER   (United States)

ⁱ UNIVERSITY OF CHICAGO MEDICAL CENTER   (United States)

^j UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

more..

Author keywords

Adenocarcinoma; Chemoradiation; Cisplatin; Interferon; Pancreas; Surgery

Indexed keywords

ALPHA2B INTERFERON; CISPLATIN; FLUOROURACIL;

ABDOMINAL PAIN; ABNORMAL LABORATORY RESULT; ADULT; AGED; ANEMIA; ANOREXIA; ARTICLE; BACKACHE; BLEEDING; BLOOD CLOTTING DISORDER; BLOOD TOXICITY; CANCER ADJUVANT THERAPY; CANCER RADIOTHERAPY; CANCER SURVIVAL; CARDIOVASCULAR DISEASE; CONTINUOUS INFUSION; DEHYDRATION; DEPRESSION; DESQUAMATION; DIARRHEA; DISEASE FREE SURVIVAL; DRUG EFFICACY; DRUG ERUPTION; DYSPHAGIA; ELECTROLYTE DISTURBANCE; EXTERNAL BEAM RADIOTHERAPY; FATIGUE; FEBRILE NEUTROPENIA; FEMALE; GASTROINTESTINAL DISEASE; GASTROINTESTINAL SYMPTOM; GINGIVITIS; HAND FOOT SYNDROME; HEMOPTYSIS; HEMORRHOID; HUMAN; HYPERGLYCEMIA; HYPERKALEMIA; HYPERTENSION; HYPOALBUMINEMIA; HYPOCALCEMIA; HYPOKALEMIA; HYPOMAGNESEMIA; HYPONATREMIA; HYPOPHOSPHATEMIA; HYPOTENSION; INFECTION; KIDNEY DISEASE; LEUKOPENIA; LIVER TOXICITY; LYMPHOCYTOPENIA; MAJOR CLINICAL STUDY; MALE; METABOLIC DISORDER; MUCOSA INFLAMMATION; MULTICENTER STUDY; NAUSEA; NEUROLOGIC DISEASE; NEUTROPENIA; OUTCOME ASSESSMENT; OVERALL SURVIVAL; PANCREAS CANCER; PANCREAS SURGERY; PARTIAL THROMBOPLASTIN TIME; PHASE 2 CLINICAL TRIAL; POLYURIA; PRIORITY JOURNAL; PROGNOSIS; PROTHROMBIN TIME; PRURITUS; QT PROLONGATION; RADIATION DOSE FRACTIONATION; SENSORY DYSFUNCTION; SIDE EFFECT; SINUS BRADYCARDIA; SKIN DISEASE; SKIN IRRITATION; SYNCOPE; THROMBOCYTOPENIA; THROMBOSIS; UROGENITAL TRACT DISEASE; VOMITING; WEIGHT REDUCTION;

EID: 79251579661     PISSN: 09237534     EISSN: 15698041     Source Type: Journal    
DOI: 10.1093/annonc/mdq384     Document Type: Article

References (22)

1. Ghaneh P, Kawesha A, Howes N et al. Adjuvant therapy for pancreatic cancer. World J Surg 1999; 23(9): 937-945.
2. Klinkenbijl JH, Jeekel J, Sahmound T et al. Adjuvant radio-therapy and 5-fluorouracil after curative resection of cancer of the pancreas and periampullary region. Ann Surg 1999; 230: 776-784.
3. Neoptolemos JP, Stocken DD, Friess H et al. A randomized trial of chemoradiotherapy and chemotherapy after resection of pancreatic cancer. N Engl J Med 2004; 350: 1200-1210.
4. Oettle H, Post S, Neuhaus P et al. Adjuvant chemotherapy with gemcitabine vs. observation in patients undergoing curative-intent resection of pancreas cancer: a randomized controlled trial. JAMA 2007; 297: 267-277.
5. Neoptolemos J, Buchler M, Stocken DD et al. ESPAC-3(v2): a multicenter, international, open-label randomized controlled phase III trial of adjuvant 5-fluorouracil/folinic acid versus gemcitabine in patients with resected pancreas cancer. J Clin Oncol 2009; 27: 18s (Suppl; Abstr. LBA4505).
6. Byfield JE, Calabro-Jones P, Klisak I et al. Pharmacological requirements for obtaining sensitization of human tumor cells in vitro to combined 5-fluorouracil and x-rays. Int J Radiat Oncol Biol Phys 1982; 13: 1691-1697.
7. Holsti LR, Mattson K, Niiraven A et al. Enhancement of radiation effects by alphainterferon in the treatment of small cell lung cancer. Int J Radiat Oncol Biol Phys 1987; 13: 1161-1166.
8. Sischy B, Doggett RLS, Krall JM. Definitive irradiation and chemotherapy for radiosensitization in the management of anal carcinoma: interim report of Radiation Therapy Oncology Group No. 8314. J Natl Cancer Inst 1989; 81: 850-856.
9. Wadler S, Wersto R, Weinberg V et al. Interaction of fluorouracil and interferon in human colon cancer cell lines: cytotoxic and cytokinetic effects. Cancer Res 1990; 50: 3473-3486.
10. Vokes EE. The promise of biochemical modulation in combined modality therapy. Semin Oncol 1994; 21(S14): 29-33.
11. Ismail A, Van Groeningen CJ, Hardcastle A et al. Modulation of fluorouracil cytotoxicity by interferon-alpha-2b and -gamma. Mol Pharmacol 1998; 53: 252-261.
12. Nukui Y, Picozzi VJ, Traverso LW. Interferon-based adjuvant chemoradiation therapy improves survival after pancreaticoduodenectomy for pancreatic adenocarcinoma. Am J Surg 2000; 179: 367-371.
13. Picozzi VJ, Kozarek RA, Traverso LW. Interferon-based adjuvant chemoradiation therapy after pancreaticoduodenectomy for pancreatic adenocarcinoma. Am J Surg 2003; 185: 476-480.
14. Regine WF, Winter KA, Abrams RA. Fluorouracil vs. gemcitabine chemotherapy before and after fluorouracil-based chemoradiation following resection of pancreatic adenocarcinoma: a randomized controlled trial. JAMA 2008; 299: 1019-1026.
15. Common Terminology Criteria for Adverse Events (CTCAE). Version 3.0. U.S. Department of Health and Human Services, National Institutes of Health, National Cancer Institute, Bethesda, MD, 2003.
16. American Joint Committee on Cancer. AJCC Cancer Staging Manual, 6th edition. New York: Springer-Verlag 2002.
17. Gastrointestinal Tumor Study Group. Further evidence of effective adjuvant combined radiation and chemotherapy following curative resection of pancreatic cancer. Cancer 1987; 59: 2006-2010.
18. Van Laetham JL, Mornex F, Azria D et al. Adjuvant gemcitabine alone versus gemcitabine-based chemoradiation after curative resection for pancreatic cancer: updated results of a randomized EORTC/FFCD/GERCOR phase II study. J Clin Oncol 2009; 27: 15s (Suppl; Abstr 4527).
19. Linehan DC, Tan MCB, Strasberg SM et al. Adjuvant interferon-based chemoradiation followed by gemcitabine for resected pancreatic adenocarcinoma: a single-institution phase II study. Ann Surg 2008; 248: 145-151.
20. Pelzer U, Kubica K, Stieler J et al. A randomized trial in patients with gemcitabine-refractory pancreas cancer: final results of the CONKO 003 study. J Clin Oncol 2008; 26: 14s (Suppl; Abstr 4508).
21. Schmidt J, Jaeger D, Hoffman K et al. Impact of interferon-alpha in combined chemoradioimmunotherapy for pancreatic adenocarcinoma (CapRI): first data from the immunomonitoring. J Immunother 2007; 30: 108-115.
22. Pisters PWT, Evans DB. Cisplatin, fluorouracil, interferon-a and radiation as adjuvant therapy for resected pancreatic cancer: is there a future for this regimen and/or should we change our approach to the research and treatment of patients with resected pancreatic cancer? Ann Surg 2008; 248: 152-153.